BiotechTube
Mo:re

Mo:re

Munich, Germany· Est.
more.science
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Mo:re is a Munich-based biotech tools company founded in 2018, focusing on automating 3D cell culture to improve the predictive power of preclinical drug development. Their platform offers standardized protocols, automated execution, and AI-assisted data analysis to produce reproducible organoid and spheroid cultures, addressing key bottlenecks in scalability and data interpretation. By enhancing the relevance and reliability of human tissue models, Mo:re targets the growing market demand for alternatives to animal testing and conventional 2D cultures. The company has gained recognition, winning the 2025 SLAS New Product Award, and appears to be in an early commercial or late development stage with its integrated hardware and software platform.

AI / Machine LearningDrug DeliveryDigital Health

Technology Platform

Integrated hardware-software platform that automates and standardizes the entire 3D cell culture workflow, including planning with standardized protocols, automated preparation and execution, and AI-assisted data analysis on a web platform.

Opportunities

The company is positioned at the convergence of strong trends: the push to reduce animal testing, the need for more predictive human-relevant models, and the demand for lab automation.
This creates a large and growing market in pharma and biotech for standardized, scalable 3D culture solutions.
Their integrated platform approach addresses a key bottleneck, offering a significant efficiency gain.

Risk Factors

Key risks include slow adoption by a conservative industry, significant competition from both large toolmakers and startups, and the technical execution risks of developing and manufacturing a complex hardware-software system.
As a private company, they also face ongoing funding risk to scale operations.

Competitive Landscape

Mo:re competes in the organoid/3D culture tools and lab automation spaces. Competitors range from large, diversified life science suppliers (e.g., Thermo Fisher, Corning) offering components and some automation, to specialized startups focusing on organoid media/matrices, imaging, or niche automation. Mo:re's differentiation is its claimed end-to-end integration of protocol standardization, physical automation, and AI-driven data analysis specifically for 3D workflows.

More companies in Diagnostics & Precision Medicine →More companies in Germany →